Retrospective review of relapse after allogeneic stem cell transplant for myeloid malignancy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...

The ORR was 70% in patients treated with remestemcel-L, with 30% having a complete response and 41% having a partial response. The Food and Drug Administration (FDA) has approved Ryoncil ® ...

Regenerative medicine company Mesoblast Ltd. received an early Christmas present from the FDA for approval of its allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, Ryoncil ...

Mesoblast (ASX:MSB) founder and CEO Prof Silviu Itescu has a markedly more relaxed demeanor than in the past, when investors ...

The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in Systemic Lupus Erythematosus) study was officially completed on February 21, 2025 ...

The company states: “Mesoblast (MESO) announced the FDA approved Ryoncil, remestemcel-L, as the first mesenchymal stromal cell, MSC, therapy in the United States. RYONCIL is the only MSC therapy ...

TIANJIN, China, Jan. 25, 2026 /PRNewswire/ -- In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal ...

USANewsGroup.com News Commentary -- The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical breakthroughs and manufacturing milestones reshaping ...